To the Editor.
—The article by Dr Weg and colleagues1 is important to all physicians treating patients with adult respiratory distress syndrome (ARDS). Though their article is listed under the heading Preliminary Communication and the primary objective is to assess drug safety, the authors have also assessed potential drug efficacy. It would be useful for readers to have further information before reaching any conclusion about this article.The authors comment that 51 patients were admitted from 20 tertiary care medical centers throughout the United States. Sepsis-induced ARDS is a common condition in most tertiary care intensive care units (ICUs). The authors do not comment on the study interval for patient enrollment, the number of patients screened for entry into the study, the number eligible for enrollment, and the reason for exclusion or refusal of subjects. These data are important if we are to be sure that the study sample
Doig C. Aerosolized Surfactant in Sepsis-Induced Adult Respiratory Distress Syndrome. JAMA. 1995;273(16):1259-1260. doi:10.1001/jama.1995.03520400029037